MYL – Strong fundamentals imply market expectations for a Uniform ROA compression to historical lows is far too bearish, even though management is concerned about near-term outlook

May 31, 2019

  • Mylan N.V. (MYL:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 7.8x Uniform P/E, implying expectations for profitability to fall to historical lows. Despite management’s concerns about rebates, product launches, and investments, given historical performance, these expectations are overly bearish, and upside is likely warranted
  • Specifically, management may be concerned about policies regarding Part D patients and rebates, the potential of 2018 product launches, and specifically their biosimilar trastuzumab launch. Moreover, they may be exaggerating the potential benefits of key brand investments, and the quality of their Rest of World portfolio
  • That said, market expectations are overly bearish, and even with potential near-term headwinds, long-term outperformance remains warranted should MYL just maintain profitability near historical averages.

You don’t have access to the Valens Research Premium Application.

To get access to our best content including the highly regarded Conviction Long List and Market Phase Cycle macro newsletter, please contact our Client Relations Team at 630-841-0683 or email

Please fill out the fields below so that our client relations team can contact you

Or contact our Client Relationship Team at 630-841-0683